NEO — NEOGENOMICS INC
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 1077183 ·
Last close
$19.33
Market Cap
$2.48B
52W High
$20.05
52W Low
$7.07
ADV30
1,899,140
Next earnings
2026-10-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 201,656,000 | 91,878,000 | -9,771,000 | 2,238,000 | 1,352,243,000 | 145,539,000 | 566,511,000 |
| Mar 2026 | 186,672,000 | 80,864,000 | -18,241,000 | -17,106,000 | 1,346,531,000 | 146,143,000 | 517,771,000 |
| Dec 2025 | 190,170,000 | 83,343,000 | -12,788,000 | -9,881,000 | 1,359,830,000 | 159,618,000 | 523,268,000 |
| Sep 2025 | 187,797,000 | 80,446,000 | -19,928,000 | -27,129,000 | 1,374,780,000 | 164,117,000 | 536,490,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$22,049,000
Investing CF
$-19,901,000
Financing CF
$-11,386,000
CapEx
$-29,404,000
Dividends Paid
—
Buybacks
$-25,000,000
EPS Diluted TTM
$-0.40
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-448,674,000
Inventory
$27,137,000
Receivables
$175,405,000
ST Investments
$0
EBIT TTM
$-51,966,000
Pretax Income TTM
$-54,547,000
Interest Exp TTM
$2,581,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$766,294,976
EBITDA
$24,325,000
Free Cash Flow
$43,904,752
Enterprise Value
$2,528,023,552
Total Cash
$145,539,008
Total Debt
$448,368,000
Shares Out
128,475,440
Trailing EPS
$-0.39
Book Value
$6.14
ROE
-6.3%
ROA
-1.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 727,332,000 | -88,128,000 | -108,025,000 | 1,359,830,000 | 523,268,000 | 836,562,000 | 5,230,000 |
| Dec 2024 | 660,566,000 | -85,448,000 | -78,726,000 | 1,638,038,000 | 735,699,000 | 902,339,000 | 7,023,000 |
| Dec 2023 | 591,643,000 | -96,648,000 | -87,968,000 | 1,681,229,000 | 739,692,000 | 941,537,000 | -1,953,000 |
| Dec 2022 | 509,728,000 | -153,107,000 | -144,250,000 | 1,740,034,000 | 742,011,000 | 998,023,000 | -65,993,000 |
TTM Snapshot
Revenues TTM
$616,595,000
NetIncome TTM
$-108,352,000
OpCashFlow TTM
$0
Assets (Latest)
$1,359,830,000
Forward EPS
$0.34
Max Pain — expiry 2026-12-18
max pain strike: $10.00 · spot: $19.26 · call oi: 7,891 · put oi: 98Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AEGXF | Aecon Group Inc. | $2.49B | $36.32 | — |
| LLYVA | Liberty Live Holdings, Inc. | $2.46B | $96.32 | — |
| LUNR | Intuitive Machines, Inc. | $2.50B | $15.61 | — |
| GDV | GABELLI DIVIDEND & INCOME TRUST | $2.51B | $28.95 | — |
| HURN | Huron Consulting Group Inc. | $2.51B | $157.98 | — |
News headlines (Yahoo Finance, 1h cache)
3 Reasons NEO is Risky and 1 Stock to Buy Instead
2026-09-22 16:21 · Yahoo
NeoGenomics (NEO) Expands Precision Oncology Focus, Is The Stock Fairly Valued?
2026-09-22 08:20 · Yahoo
Is NeoGenomics’ (NEO) Community NGS Push Quietly Redefining Its Core Earnings Engine?
2026-09-21 13:13 · Yahoo
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference
2026-09-21 02:02 · Yahoo
1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down
2026-09-18 12:40 · Yahoo
A Look Back at Testing & Diagnostics Services Stocks’ Q2 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack
2026-09-11 12:11 · Yahoo
NeoGenomics Stock Just Turned Its First Profit, Creating an Optimal Entry Point
2026-08-27 15:45 · Yahoo
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
2026-08-26 20:17 · Yahoo
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
2026-08-27 03:13 · Yahoo
Why Women-Run Companies Deserve a Place in Your Portfolio
2026-09-24 16:42 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.